![institutions-DFCI-Logo-500px-rgb[2]20221027132117.jpg](/images/institutions/logos/DFCI-Logo-500px-rgb[2]20221027132117.jpg){kind=logo}
In a new study, researchers at Dana-Farber Cancer Institute used cryo-electron microscopy to reveal for the first time how one IAP, a protein called BIRC6, operates at a molecular level to inhibit programmed cell death.
The second season of Unraveled: A Dana-Farber Cancer Institute podcast is now available with six new episodes telling stories of the science and scientists behind some of the most important cancer discoveries, diving deep into the lab.
In an internationally conducted clinical trial lead by Dana-Farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab soravtansine resulted in substantially better responses than standard treatments. Mirvetuximab soravtansine was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in November 2022.
This study provides a mechanism for rapidly identifying the protein kinase that is driving the abnormal behavior of individual cancers.
A combination of two next-generation immunotherapy drugs has shown promising clinical activity in treating patients with refractory metastatic colorectal cancer, a disease which has not previously responded well to immunotherapies, according to a Dana-Farber Cancer Institute researcher.
Rachel Pozzar, PhD, RN, a nurse scientist in the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, has been awarded the 2023 Oncology Nursing Society’s (ONS) Victoria Mock New Investigator Award.
A paper posted online by JCO Precision Oncology reports that a molecular tumor board program has largely fulfilled expectations, providing expert treatment guidance for more than 500 patients over the six-month evaluation period and identifying clinical trials appropriate for the majority of them. Overall, the team has reviewed test results for more than 2,700 patients to date. The findings suggest that the program can be a model for other cancer centers.
A new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute pinpoints which clonal hematopoiesis patients are at highest risk for cancer progression.
Study uncovers the genomic features of Richter's and how it emerges from CLL Researchers identify molecular subtypes of Richter's and y show that, in some cases, Richter's can be detected in a blood test, rather than a biopsy, potentially leading to earlier treatment.
Scientists at Dana-Farber Cancer Institute have developed a drug that potently neutralizes SARS-CoV-2, the COVID-19 coronavirus, and is equally effective against the Omicron variant and every other tested variant. The drug is designed in such a way that natural selection to maintain infectiousness of the virus should also maintain the drug’s activity against future variants.
Four recipients of the Lubin Family Foundation Scholar award are announced -- these scholars are among the most promising physician-scientists and are on track to becoming the next generation of leaders in cancer research.
Marvel Studios’ movie, “Black Panther: Wakanda Forever,” is the highly anticipated sequel to “Black Panther,” hitting theaters on November 11th. It will premiere without “Black Panther” star Chadwick Boseman, who passed away in 2020 from colorectal cancer at the age of 43. Boseman’s death was a stark reminder of the alarming rise in colorectal cancer in patients younger than 50, as well as the higher incidence and mortality of this disease in the non-Hispanic Black population.
Patients with cancer and a weakened immune system who are treated with immunotherapies tend to fare far worse from COVID-19 than those who haven't received such therapies in the three months before their COVID diagnosis, show findings in a new study by researchers at Dana-Farber Cancer Institute, and across the U.S., Canada, and Mexico. Researchers found worse outcomes in both the disease itself as well as the fierce immune response that sometimes accompanies it.
As more patients with cancer have their tumors genomically profiled, and more therapies targeting genomic alterations enter clinical trials, the task of connecting patients to trials for which they are eligible can be especially challenging. A computer platform developed at Dana-Farber Cancer Institute makes the matching process both easier and faster, its designers report in a new study.
Dana-Farber Cancer Institute is becoming a member of the Parker Institute for Cancer Immunotherapy
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.
Combination therapies show encouraging results in several studies led by Dana-Farber Cancer Institute and presented for the first time at the European Society of Medical Oncology (ESMO) Congress 2022, Paris, France. The studies will be presented both in-person and online on September 9-13, 2022.
Sexual dysfunction is highly prevalent in women with lung cancer with most survey participants reporting little to no interest in sexual activity, according to research led by Narjust Florez (Duma), MD, associate director for the Cancer Care Equity Program at Dana-Farber Cancer Institute. The research was presented today at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2022.
Laurie H. Glimcher, MD, president and CEO of Dana-Farber Cancer Institute is among the 2022 class of Modern Healthcare’s 50 Most Influential Clinical Executives award. The 50 Most Influential Clinical Executives award program honors individuals in healthcare who are deemed by their peers and the senior editors of Modern Healthcare to be paving the way to better health through their executive responsibility, leadership qualities, innovation, community service and achievements inside and outside of their respective organizations“Clinician leaders have shouldered a heavy load for healthcare organizations and the country at large throughout the past few years.
U.S. News &World Report has named Dana-Farber/Boston Children's Cancer and Blood Disorders Center #1 in the nation in its 2022-23 Best Children's Hospitals report. Dana-Farber/Boston Children's has been recognized as one of the top three pediatric cancer centers in the country each year since the ranking's inception, earning more #1 rankings than any other program.
L’Institut Servier, Gustave Roussy (Villejuif, France), and Dana-Farber Cancer Institute (Boston, USA) have signed a cooperation agreement to foster exchange and develop bilateral collaboration among researchers from these two renowned oncology centers. The two-year agreement includes the organization of annual conferences, alternating between Boston and Paris, and the establishment of a fellowship program for four young researchers, post-doctoral students from Gustave Roussy, who will be hosted in research labs of Dana-Farber.
Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of a study led by Dana-Farber Cancer Institute investigators.
Children with high-risk neuroblastoma had worse outcomes if they were from certain racial/ethnic groups or were on public rather than private insurance, despite being treated in clinical trials with standardized protocols, according to a study led by investigators from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with multiple myeloma and breast cancer. The results of these studies, along with dozens of others led by Dana-Farber researchers, will be presented at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Dana-Farber Cancer Institute names new Senior Vice President, General Counsel and Chief Governance Officer
After a nationwide search, Ian Matthew-Clayton named Vice President and Chief Inclusion, Diversity, and Equity Officer. The appointment is effective April 25, 2022.
The Gairdner Foundation has announced that Stuart H. Orkin, MD, is one of the 2022 Canada Gairdner Award laureates for seminal discoveries and contributions to biomedical science.
Letrozole and abemaciclib cause tumor shrinkage or stabilization in 75% of patients in phase 2 trial. Approximately 30% of trial participants had their tumors shrink by more than 30%
Dana-Farber Cancer Institute researchers will present important research studies during the 2022 ASCO Genitourinary (GU) Cancers Symposium. The Dana-Farber led research exemplifies innovative and multidisciplinary expertise in prostate, kidney, and bladder cancers, and includes studies examining quality of life and the impact of the COVID-19 pandemic specifically on GU malignancies.
Boston magazine has named more than 110 physicians affiliated with Dana-Farber Cancer Institute to its annual "Top Doctors" guide.
The human immune system, that marvel of complexity, subtlety, and sophistication, includes a billion-year-old family of proteins used by bacteria to defend themselves against viruses, scientists at Dana-Farber Cancer Institute and in Israel have discovered.
Two recent studies by Dana-Farber Cancer Institute scientists correct a longstanding misconception about the origins of Barrett’s esophagus, and in doing so may point to new avenues of treatment or prevention to lower the risk of esophageal cancer.
Young patients with chronic lymphocytic leukemia (CLL) can enjoy long remissions on the drug ibrutinib, but must stay on it indefinitely to keep the cancer in remission. A new study by Dana-Farber Cancer Institute researchers suggests that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy can provide deep, and lasting remissions of the disease.
For patients with the blood cancer multiple myeloma, vaccination against COVID-19 provides some protection against coronavirus infection but to a far lower degree than the general population of cancer survivors, a new study by Dana-Farber Cancer Institute investigators shows.
The first results from the largest screening study yet conducted in the U.S. of individuals at above-average risk for the blood cancer multiple myeloma have revealed higher rates of a myeloma precursor condition in older adults who are Black or who have a close family member with a current or past blood cancer.
A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
Even though young patients with metastatic colorectal cancer tend to be more fit and receive more intensive treatment than older patients, both groups survive for roughly the same amount of time, according to a new study by Dana-Farber Cancer Institute investigators.
A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need.
More than half of patients with non-small cell lung cancer (NSCLC) bearing a mutation in the HER2 gene had their tumors stop growing or shrink for an extended time after treatment with a drug that hitches a chemotherapy agent to a highly targeted antibody, an international clinical trial led by investigators at Dana-Farber Cancer Institute has found.
Consuming higher amounts of Vitamin D – mainly from dietary sources – may help protect against developing young-onset colorectal cancer or precancerous colon polyps, according to the first study to show such an association.
The Intermediate Clinical Endpoints of Cancer of the Prostate (ICECaP) working group, led by Dana-Farber Cancer Institute researchers, is being honored by the American Statistical Association (ASA) with the 2021 Statistical Partnerships Among Academe, Industry, and Government (SPAIG) Award.
Dana-Farber Cancer Institute is launching a new podcast series, titled Unraveled, to explain the science behind some of the most important breakthroughs in cancer research.
Dana-Farber Brigham Cancer Center is ranked #4 as a Best Hospital for cancer care by U.S. News and World Report for 2021-22
A new study by Dana-Farber Cancer Institute researchers has given scientists their first look at the genomic landscape of tumors that have grown resistant to drugs targeting the abnormal KRASG12C protein. Their work shows that, far from adopting a common route to becoming resistant, the cells take a strikingly diverse set of avenues, often several at a time. The findings, reported online today in the New England Journal of Medicine, underscore the need for new drugs that inhibit KRAS differently than current agents do.
An antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets and kills cancer cells with a common genetic defect, laboratory research by Dana-Farber Cancer Institute scientists shows. The findings have spurred investigators to open a clinical trial of the drug, novobiocin, for patients whose tumors carry the abnormality.
Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.
In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive a median of six and a half years after treatment.
Dana-Farber Cancer Institute researchers are presenting dozens of research studies at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO). The studies will be presented during the virtual program on June 4-8, 2021. ASCO is the world’s largest clinical cancer research meeting, attracting more than 30,000 oncology professionals from around the world.
A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients. Dana-Farber Cancer Institute investigators co-led the study.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
